These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status? Clark GM J Natl Cancer Inst; 1998 Sep; 90(18):1320-1. PubMed ID: 9747858 [No Abstract] [Full Text] [Related]
64. Breast cancer: prevention, prediction, and treatment. Mariani SM MedGenMed; 2003 Apr; 5(2):24. PubMed ID: 14603123 [No Abstract] [Full Text] [Related]
65. [Chemotherapy and immunotherapy of metastasized breast carcinoma]. Heinemann V Internist (Berl); 2002 Mar; 43(3):354-63. PubMed ID: 11963720 [No Abstract] [Full Text] [Related]
66. Milder regimen forestalls return of breast tumors. Cancer Discov; 2015 Mar; 5(3):OF1. PubMed ID: 25660160 [No Abstract] [Full Text] [Related]
67. Patient profiling in breast cancer--is knowledge power? Kirk R; Villanueva MT; Hutchinson L Nat Rev Clin Oncol; 2011 Dec; 9(1):1. PubMed ID: 22186933 [No Abstract] [Full Text] [Related]
69. Spotlight on neoadjuvant therapy for breast cancer. Boughey JC; Hunt KK Ann Surg Oncol; 2015 May; 22(5):1406-7. PubMed ID: 25727559 [No Abstract] [Full Text] [Related]
70. The incredible shrinking problem of the device patient. Kanal E Heart Rhythm; 2016 Nov; 13(11):2269-2270. PubMed ID: 27503477 [No Abstract] [Full Text] [Related]
71. Shrinking the LC landscape. Harris CM Anal Chem; 2003 Feb; 75(3):64A-69A. PubMed ID: 12585456 [No Abstract] [Full Text] [Related]
73. Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer. Montemurro F; Aglietta M Clin Breast Cancer; 2005 Apr; 6(1):77-80. PubMed ID: 15899075 [TBL] [Abstract][Full Text] [Related]
74. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM; J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968 [TBL] [Abstract][Full Text] [Related]
75. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566 [TBL] [Abstract][Full Text] [Related]
76. Herceptin (trastuzumab): adjuvant and neoadjuvant trials. Yaal-Hahoshen N; Safra T Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172 [No Abstract] [Full Text] [Related]
77. Shrinking the tumor, shrinking the patient sample size: the early disclosure dilemma. Puglisi F; de Azambuja E; de Castro G; Demonty G J Clin Oncol; 2005 Sep; 23(27):6803-4; author reply 6804-5. PubMed ID: 16170195 [No Abstract] [Full Text] [Related]
78. Safety and efficacy of neo-adjuvant sequential dose-dense chemotherapy doublets combined with trastuzumab in patients with HER-2-positive early stage breast cancer. Sánchez-Muñoz A; García-Tapiador AM; Dueñas-García R; Jaén-Morago A; Ortega-Granados AL; Martínez-Ortega E; Fernández Morales M; Fernández-Navarro M; de la Torre Cabrera C; Dueñas B; Ureña C; Martínez J; Morales F; Ramírez-Tortosa C; Sánchez-Rovira P Breast J; 2008; 14(5):506-7. PubMed ID: 18705667 [No Abstract] [Full Text] [Related]